Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-022457
Filing Date
2020-05-07
Accepted
2020-05-07 10:19:38
Documents
71
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q mcrb-10q_20200331.htm 10-Q 2088365
2 EX-10.1 mcrb-ex101_102.htm EX-10.1 11946
3 EX-10.2 mcrb-ex102_103.htm EX-10.2 210302
4 EX-31.1 mcrb-ex311_10.htm EX-31.1 10562
5 EX-31.2 mcrb-ex312_8.htm EX-31.2 10487
6 EX-32.1 mcrb-ex321_6.htm EX-32.1 7358
7 EX-32.2 mcrb-ex322_11.htm EX-32.2 7456
  Complete submission text file 0001564590-20-022457.txt   6723007

Data Files

Seq Description Document Type Size
8 XBRL INSTANCE DOCUMENT mcrb-20200331.xml EX-101.INS 1292774
9 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20200331.xsd EX-101.SCH 50054
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE mcrb-20200331_cal.xml EX-101.CAL 45193
11 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mcrb-20200331_def.xml EX-101.DEF 132227
12 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20200331_lab.xml EX-101.LAB 393507
13 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20200331_pre.xml EX-101.PRE 281289
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

EIN.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37465 | Film No.: 20854972
SIC: 2834 Pharmaceutical Preparations